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ABSTRACT 
Nonionic surfactant based vesicles which are uni/multilamellar in structures are called niosomes. These vesicles contains an aqueous interior 
surrounded by one or more amphiphilic bilayer membrane forming surfactant which separates them from the bulk solution, and are also called as 
supramolecular aggregates. Niosomes, being an efficient drug delivery system, investigations are carried out to utilize this system to treat various 
disorders, to promote improved patient compliance, lesser side effects, reduction in dose, lesser dosage frequency, and higher amount of the drug at 
the particular site so as to lessen an excessive contact with the whole body. The Pharmacokinetic and Pharmacodynamic profile of Niosomal drug 
delivery system vary for various entrapped drugs. Drugs that are successful in the mitigation or treatment of CNS disorders should cross the BBB to 
reach the brain, as BBB seems to be an obstacle for a large number of drugs, including CNS active drugs. This article compiles recent techniques for 
the preparation and characterization of niosomes, the effect of formulation variables on its physicochemical properties and discussed about its 
effective applications in drug delivery.  
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Nonionic surfactant based vesicles which are uni/multilamellar in 
structures enclosing lipophilic components and an aqueous solution 
of solutes are called niosomes. These vesicles are produced by the 
self-assembly of hydrated surfactant monomers. Compared to 
liposomes, niosomes overcomes the stability associated problems 
which includes oxidation, high economy, a purity that influences on 
size and shape. Niosomes are capable of entrapping both hydrophilic 
and lipophilic drugs in the aqueous layer and vesicular membrane 
and are represented in fig. 1. The bilayers of niosomes have 
sandwiched lipophilic area in between the hydrophilic inner and 
outer surfaces of the bilayers. Hence drugs can be delivered 
extensively along with other required materials using niosomes. In 
recent years, these were extensively studied for their modified 
potential of the biodistribution and activity profile of the drug. It acts 
as a carrier in the release of medicaments, hormones, antigens, and 
bioactive molecules. Moreover, niosome also acts as an alternate 
version to unravel the problem of insolubility, unsteadiness and 
rapid deprivation of drugs [1].  
Brain is a delicate organ, more efficiently protected by the nature by 
itself. Brain is protected against toxic substances by two major 
barrier systems namely the blood-brain barrier (BBB) and blood-
cerebrospinal fluid barrier (BCSFB). The morphological and 
physiological characteristics of barriers are distinct, based on their 
different tasks [2]. Brain endothelia comprises of brain capillary 
endothelium forming "tight junctions"/zonulaoccludens is known as 
BBB, which prevents migration or cell movement across endothelial 
cells [3]. As a result of its stringent permeability, it restricts the 
entry of hopeful drugs to target brain tissues and is accepted to be 
the key hurdle in mounting CNS drugs [4]. 
 
 
Fig. 1: Schematic representation of a Niosome 
 
Surfactants  
Surfactants and their combinations in various molar ratios are used 
to entrap numerous drug moieties in niosomes of varying sizes [5]. 
Nonionic surfactants have high interfacial activity and composed of 
both polar and nonpolar segments. Hydrophilic-lipophilic balance 
(HLB) of the surfactant, chemical structure of the components and 
critical packing parameter (CPP) are the key factors for the 
formation of bilayer vesicles [6].  
Critical packing parameter can be determined by the self-assembly 




Hydrophobic tail volume (V), Hydrocarbon tail area (Ic), and 
Hydrophilic head group area (a) is also shown in fig. 2. 
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( ) 0.5  1CPP Between to : Spherical vesicles form 
( )   0.5   CPP < : Micelles form 
( )  1   CPP > : Inverted-micelles form 
Fig. 2: Critical packing parameter [7] 
 
Entrapment efficiency of the drug is highly affected by the size of the 
hydrophilic head group and chain length of the nonionic surfactant. 
Stearyl (C18) chains of nonionic surfactants showed merely higher 
entrapment-efficiency compared with lauryl chains (C12). Studies 
showed maximum entrapment efficiency for water-soluble drugs 
when various tweens bearing a long alkyl chain and a large 
hydrophilic moiety are combined with the Cholesterol [8]. 
Ether-linked surfactants 
Polyoxyethylene alkyl ethers are surfactants in which hydrophilic and 
hydrophobic moieties are linked with ether group. The General 
formula of Polyoxyethylene alkyl ethers is CnEOm, where n can be 12-
18 and m can be 3-7. Surfactants with Polyhydroxyl head and ethylene 
oxide units are reported in various niosomal formulation [9]. 
The hydrophilic and hydrophobic group of the surfactant linked with 
ester moiety have been applied for the preparation of sodium 
stibogluconate and to deliver it towards the marine visceral 
leishmaniasis [10].  
Sorbitan esters 
Ester-linked surfactants are derivatives of Polyoxyethylene esters 
used in the cosmetic industry for the preparation of water-based 
products. They are also referred to as spans. Mostly the spans are 
used to solubilize the essentials oils which are used in cosmetic 
preparations. Spans with high molecular weight produces less leaky 
vesicles which are more stable to osmotic gradient [11]. 
Alkyl amides  
Alkyl amides vesicles are supramolecular assemblies produced by 
incorporating amino acid spacers in alkyl galactosides and 
glucosides. Alkyl amides have alkyl groups that are fully/partially 
saturated hydrocarbons having a chain length of C12 to C22 with 
few fluorocarbon chains having newer amide like compounds [11]. 
Fatty acids and amino acid compounds  
Amino acid moieties becomes amphiphilic when fatty acids are used. 
The vesicles are formed with hydrophobic alkyl side chains, whereas 
long chain fatty acids forms closed vesicles which are called as 
“Ufasomes” [11]. 
Cholesterol 
An important component of a cell membrane showing noticeable 
changes in bilayer fluidity and permeability. Cholesterol is usually 
incorporated into non-ionic surfactants in large molar ratios to 
provide rigidity and orientational order. Cholesterol is an 
amphiphilic molecule, which orients the aliphatic chain in the 
direction of surfactant’s hydrocarbon chain and OH group in the 
direction of the aqueous phase. Rigidization is provided by 
alternative positioning of a rigid steroidal skeleton with surfactant 
molecules in the bilayer. It also prevents leakage by eliminating gel 
to liquid phase transition [11]. 
Charge inducers  
The stability of the vesicle is increased by charge induction on the 
surface of prepared vesicles. The zeta potential of vesicles are higher 
and it prevents the aggregation of vesicles due to the repulsive 
forces of the same charges. The frequently used positive charge 
inducers are cetyl pyridinium chloride and sterylamine and negative 
charge inducers are dihexadecyl phosphate, lipoamine acid and 
dicetyl phosphate [12]. 
Choice of surfactant and stabilizer 
In the niosomal formulation, selection of surfactant and stabilizer 
plays the major role in the optimization of invitro release, required 
size distribution, entrapment efficiency and viscosity etc. Studies 
showed that zidovudine (BCS Class III) niosomes prepared with 
Tween 80 as surfactant and DCP as stabilizer (-ve charge-inducer) 
effectively entrapped high amounts of drug and released 88.72% of 
drug over 12 h [13]. Ammar HO et al. investigated that Diltiazem 
(BCS Class I) niosomes prepared with span 60 and Cholesterol (1:1 
molar ratio) showed maximum entrapment efficiency and drug 
release on in-vitro investigation and in-vivo study exhibited an 
increase in MRT, t1/2 and AUC with a decrease in Ke [14]. 
Griseofulvin (BCS Class II) niosomes are prepared by thin film 
hydration technique with cholesterol, span 60, and DCP in the ratio 
of 75:75:1.5 exhibited maximum entrapment efficiency. In 
Griseofulvin niosomes, DCP imparts a negative charge to the bilayer 
vesicles as they are found to be more competent for drug delivery 
and provides stability to the system, prevents agglomeration and 
aggregation of vesicles [15]. 
Nagaraju Ravouru et al. developed Folic acid (BCS Class IV) 
niosomes for brain targeting with span60 and cholesterol 
(stabilizing agent) in the ratio of 1:1 (50 mg: 50 mg), showed the 
entrapment efficiency of about 69.42% with better in-vitro drug 
release profile of 64.2% at the end of 12 h [16]. 
Techniques of preparation 
Vesicles of niosomes are produced by various techniques as shown 
in Fig.3. Some of the methods are suitable for large-scale, and others 
are suitable for small scale. 
Mothilal et al. 




Fig. 3: Formulations of noisome 
 
Thin film hydration  
Surfactant, cholesterol and charge inducers are the vesicles forming 
components, are solubilised in a round bottom flask having an 
organic solvent which is volatile in nature. Formation of thin, dry 
film containing dissolved components is achieved by evaporating 
the organic solvent at room temperature using Rotovac evaporator. 
Formations of niosomes are achieved by hydration and gentle 
agitation of the dried thin film with aqueous phase [17, 18].  
Ether injection  
In this method, surfactant, cholesterol and other substances are 
solubilized in diethyl ether and slowly injected into an aqueous 
phase at 60 °C using 14 gauge needle, leading to the evaporation of 
the ether and forming single layered vesicles. The control of the size 
of the vesicles can be observed by controlling the size of the needle 
and other conditions. This process finds its disadvantage of material 
solubilization in ether and removal of same from the final 
formulation with a great difficulty [19].  
Reverse phase evaporation  
In this process, surface active agents are solubilised in a mixture of 
organic solvents which is volatile in nature, such as ether and 
chloroform followed by the drug in an aqueous phase. Water in oil 
(W/O) emulsion of the two phases in a bath-sonicator yields 
niosomes upon evaporation of an organic solvent. The emulsion 
obtained from this process is dried in a Rotovac evaporator at 40 °C 
to form a semi-solid gel first and consequently hydrates to fig. large 
vesicles. A small quantity of buffer is added to the semi-solid gel and 
sonicated at 4-5 °C to produce unilamellar vesicles which are 
smaller in size [20]. 
Microfluidization 
This technique involves an interaction chamber where two phases 
interact at ultra-high speed in microchannels. Niosomes which are 
small and uniform are formed due to high-speed impingement and 
the energy with a high degree of reproducibility [21]. 
Sonication  
Surfactant-cholesterol mixture is dispersed in the aqueous phase. 
The dispersed phase is probe sonicated for 10 min at 60 °C to 
produce multilamellar vesicles (MLV), further increase in sonication 
time produce uni-lamellar vesicles [22, 23].  
The bubble method  
This is a single step process without the action of the organic solvent. 
A buffer is used for the all the components to disperse and kept in a 
three-necked round bottom flask attached to water cooled-reflux 
having the nitrogen supply along with a thermometer. The said flask 
was immersed in a water bath having controlled temperature. Finally, 
the dispersion was mixed with a shear homogenizer for 15 seconds 
and bubbled with nitrogen assembly to yield niosomes [24]. 
Active trapping techniques  
In this method, the pH or ion gradient is maintained at optimum to 
yield niosomes having high drug-lipid ratios and absence of leakage 
with 100% entrapment efficiency. This is suitable for labile drugs [25]. 
Tran’s membrane pH gradient  
In this process, the components are solubilized in the organic phase 
and allowed to evaporate to form a thin layer. The thin layer is 
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further hydrated with citric acid to produce multilamellar vesicles. 
The formed multilamellar vesicles are freeze-thawed three times 
and sonicated to form a suspension. To this suspension an aqueous 
solution containing drug is added, vortexed and pH was raised to 
7.0-7.2 using 1M disodium phosphate. The suspension is subjected 
to 60 °C for 10 min to produce drug loaded niosomes [26]. 
Formation of niosomes from proniosomes 
The proniosomes are obtained as a dried product, in which sorbital is 
used as a water-soluble carrier and are coated with a thin film of dry 
non-ionic surfactants. They were renowned by the adding up of aqueous 
phase at (T>Tm) and concise confrontation concomitantly [27].  
( ) ( )   T m Temperature Mean phase transition temperatureΤ −> >  
Multiple membrane extrusion methods 
This can be used for the production of multi as well as large 
unilamellar vesicles, and its size can be condensed by fleeting 
through a membrane filter. It is also a reliable way for the 
production of niosomes with controlled vesicle size [28]. 
The handjani–vila method 
In this method, non-ionic synthetic lipids are mixed with an 
equivalent amount of drug aqueous solution to be encapsulated. The 
lipid-oil mixture is shaked to form a homogenous lamellar film. The 
mixture is further homogenized at a controlled temperature by 
using ultracentrifugation and agitation [29]. 
The enzymatic method 
The ester links are cleaved by the esterases, and Cholesterol and 
surfactants such as polyoxyethylene cholesteryl sebacetate 
diacetate and Polyoxyethylene stearyl derivatives combine with 
diacetyl phosphate and other lipids to produce multilamellar 
niosomes [30]. 
The single pass technique 
Michael W et al. patented a continuous process, in which the solution 
or suspension of lipids are extruded with high pressure through a 
porous device and a nozzle followed by homogenization to form 
niosomes of narrow range 50-500 nm size distribution [31]. 
 
Table 1: Methods of preparation with various Non-ionic surfactants and stabilizer with its applications 
Method Non-ionic surfactant and 
stabilizer 
Drug Applications Reference 
Thin film-hydration 
technique 
Span 60, Cholesterol Diltiazem Calcium channel blocker; hypertension, angina 




Span 60, Cholesterol Diacerein Inhibiting interleukin-1 beta; Osteoarthritis 32 
Sonication Method Span 60, Cholesterol, 
dicetylphosphare (DCP), 
stearylamine (SA) 
Candesartan Angiotensin II receptor antagonist; 
Hypertension 
33 
Lipid film hydration 
method 
Span 60, Cholesterol Loratadine Antihistamine; Allergies 34 
Thin film hydration 
method, an Ether 
injection method 
Tween 40, cholesterol Ketoprofen Nonsteroidal anti-inflammatory drugs 
(NSAID); Inhibiting synthesis of prostaglandin. 













Span 60, Cholesterol, 
Dicetylphosphate (DCP) 
Tenofovir To treat chronic (long term) HBV 37 
Lipid layer hydration 
method 
Span 60, Cholesterol Folic acid Anaemia 16 
Thin film hydration 
technique 
Span 60, Cholesterol, 
Dicetylphosphate (DCP) 
Clarithromycin To treat Bacterial infections 38 
Thin film-hydration 
technique 
Tween 80, Cholesterol, 
Dicetylphosphate (DCP) 
Zidovudine NRTIs; Nucleoside reverse transcriptase 
inhibitors; to prevent passing the HIV to the 
unborn baby in pregnant women 
15 
Lipid layer hydration 
method, Thin film ether 
injection method 








Span 80, Cholesterol 
Acyclovir Anti-viral infections 39 
Table 1 identified the important methods used to formulate the niosomes using various non-ionic surfactants and stabilizers. It also postulated that 
many of the niosomal formulations were prepared with span 60 as a non-ionic surfactant and cholesterol as a stabilizer for encapsulation of various 
drugs.  
 
Characterisation of niosomes 
Morphology 
Niosomal vesicles shape is assumed to be spherical. Mean diameter can 
be determined by laser light scattering method [40]. The diameter of 
vesicles can also be determined by electron microscopy, freeze-fracture 
electron microscopy, molecular sieve chromatography, 
ultracentrifugation, photon correlation microscopy and optical 
microscopy [41
Bilayer formation 
, 42]. Fusion of vesicles during the cycle might be 
attributed to the increase in vesicle diameter due to freeze-thawing of 
niosomes. 
X-cross formation under light polarisation microscopy characterizes 
the formation of bilayer vesicle owing to the assembly of non-ionic 
surfactants [43
Number of lamellae 
]. A diagrammatic representation of such formation is 
shown in fig. 4. 
Determined by using nuclear magnetic resonance (NMR) spectroscopy, 
small angle X-ray scattering and electron microscopy [44
Membrane rigidity 
]. 
Measured by the mobility of a fluorescence probe as a function of 
temperature. 
Entrapment efficiency 
Once niosomal dispersion is formulated, an unentrapped drug is 
separated. The entrapped drug remained in niosomes is determined 
by complete vesicle disruption using 50% n-propanol/0.1% Triton X-
100. The resultant solution is tested by appropriate assay method of 
the drug [45].  
It can be represented as:  
( ) ( )   100Entrapment efficiency EE Amount entrapped total amount= / ×  
Mothilal et al. 




Fig. 4: Formation of bilayer assembly of span 60 noisome [43
In vitro release study 
] 
In-vitro release rate study was reported by using dialysis tubing 
[46]. Initially, dialysis sac was washed with distilled water, followed 
by soaking, and the vesicle suspension was pipette into a bag made 
up of the tubing, finally sealed. In a 250 ml beaker, the bag 
containing vesicles was placed in 200 ml buffer solution at 25 °C or 
37 °C with constant shaking. By an appropriate assay method with a 
range of time intervals, the buffer was analysed for the drug content.  
Gel filtration technique was used for the separation of free Isoniazid 
from Isoniazid encapsulated niosomes using Sephadex G-50 powder 
soaked for 48 h in double distilled water for swelling [47]. In this 
process about 1 ml of prepared niosomal suspension was placed 
over the top of the column and elution is carried out using normal 
saline. Followed by the free drug, a slightly dense, white opalescent 
suspension of encapsulated isoniazid niosomes elutes out. In a 
dialysis tube separated niosomes were filled and was attached to 
one end. Finally, dialysis tube was suspended in phosphate buffer of 
pH (7.4), with a frequent stirring with a magnetic stirrer. The 
samples were withdrawn at specific time intervals and tested using 
high-performance liquid chromatography (HPLC) method. 
In vivo release study 
In vivo release study was performed using albino rats. These albino 
rats were differentiated into various groups. By means of 
appropriate disposal syringe, a niosomal suspension was injected 
intravenously through a tail vein for in vivo study. 
 
Table 2: Characterization parameters 
Parameters Units Instruments Reference 
Particle size determination Nm Optical Microscopy, Dynamic light scattering 16, 36, 37 
Vesicle morphology and Size 
analysis 
Nm Transmission electron microscopy 
Scanning electron microscope 
35, 36, 37 
Entrapment Efficiency % Exhaustive dialysis method, Sephadex G-50 minicolumn centrifugation method, 
Centrifugation method Refrigerated centrifuge Sonication Ultracentrifugation 
32, 34, 36 
Viscosity poise Ostwald's viscometer, Brookfield synchro electroviscometer 33, 34 
Osmotic shock Nm Optical microscopy 15, 39 
Invitro drug release % Membrane diffusion Technique, Dialysis method, Spectrophotometric determination 
Franz diffusion cell 
16, 37 
Stability studies % Drug retention behaviour 16, 37 
Zeta potential mV Zetasizer, Dynamic light scattering technology, NanoZS-90 zetasizer, Malvern zetasizer 
Nano ZS 
33, 36 
In vitro skin penetration study % Vertical franz-type diffusion cell 32 
Flow properties - Angle of repose 34 
Consolidation and compressibility - Hausner index (HI) 35 
Ex vivo and In vivo studies % Animal models 36, 37 
Table 2 summarizes the various parameters such as Particle size determination, Vesicle morphology and Size analysis, Entrapment Efficiency; 
stability studies etc., to assure the niosomal drug delivery system as a competent approach towards the novel drug delivery.  
 
Formulations and routes of administration  
In designing a vesicular formulation, the route of administration 
plays a major role. Among the various types of formulations, 
niosomes can be one of the potential oral drug delivery. Niosomes of 
gliclazide being a promising delivery system with enhanced 
bioavailability and prolonged drug release profile for the treatment 
of diabetes mellitus [48]. 
Transdermal therapeutic systems are effective dosage forms as they 
are self-contained and self-discrete dosage forms. They deliver the 
drug when applied to the intact skin in a controlled rate into the 
systemic circulation with a slow penetration, a major downside of 
transdermal drug delivery. In this case, niosomes can effectively 
increase the penetration rate when the transdermal delivery of the 
drug is incorporated. Using thin film hydration technique, and with 
various ratios of non-ionic surfactants such as Tween 20, Tween 40, 
Tween 60, and Tween 80 niosomes of terbinafine hydrochloride was 
formulated [49]. Some of the recent reports on brain-targeted drug 
delivery on Nanoemulsion includes Palperidone or curcumin micro-
emulsion [50] or Quetiapine nanoemulsion [51]. 
Gel formulation is quite eminent for intranasal delivery. Various 
polymers comprising synthetic/natural polymers are converted into 
gel form by shifting pH/temperature are used in gel formulations 
[52]. Drugs such as Ropinirole [53], Levadopa [54], Midazolam [55] 
have been developed as an in-situ nasal thermoresponsive gel 
delivery system and showed efficient brain-targeted drug delivery 
via intranasal route. However, the effect of temperature on such 
dosage form needs significant assessment [56]. 
Niosomes-advantages  
Niosomes offers better patient compliance and therapeutic effect 
with greater bioavailability compared to conventional dosage forms 
[57, 58]. The depot formation of noisome shows controlled and 
sustained release of drugs [59, 60]. The remarkable capability of 
noisome is to entrap hydrophilic drugs, lipophilic drugs as well as 
amphiphilic drugs [61]. The size, shape, fluidity, composition, of 
drug-containing niosomes can be controlled whenever necessary.  
Niosomes are successfully used in targeting drugs to several organs [62]. 
Compared to liposomes, niosomes are more stable [63] and can raise the 
permeation of drugs in the skin [64]. The routes of administration of 
Mothilal et al. 
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niosomes can be widened like oral, parenteral and topical etc. [65]. 
Niosomes are biodegradable, biocompatible and non-immunogenic to 
the body. In the case of niosomes the handling, storage, and 
transportation are quite easier than any other formulations [66]. 
 
Table 3: Non-ionic surfactants with various routes of administration 
Non-ionic surfactant Stabilizer Ratio Route of administration Reference 
Span 60 Cholesterol 1:1 Nasal 14 
Span 60 Cholesterol 9:1 Topical 32 
Span 60 Cholesterol, Dicetylphosphate (DCP) 1:1:0.05 Oral 33 
Span 60 Cholesterol 1:1 Nasal 34 
Tween 40 Cholesterol 1:1 Topical 35 
Span 60 Cholesterol 1:1 Topical 36 
Span 60 Cholesterol, Dicetylphosphate (DCP) 1:1 Oral 37 
Span 60 Cholesterol 1:1 Nasal 16 
Span 60 Cholesterol 1:1 Oral 38 
Span 60 
Span 60 And Span 80 








From the table 3 it is understood that niosomes are successfully employed in the oral and topical formulations and recently niosomal formulations 
are being employed via nasal route. 
 
Application of niosomes 
Niosomes have been widely applied in diverse fields to treat various 
diseases, diagnostics, and cosmetics. Niosomes have a wide range of 
pharmaceutical drug delivery application owing to their inherent 
advantages.  
Immuno-niosomes 
Niosomes conjugation to antibodies forms immune-niosomes on 
their surface. Incorporation of cyanuric chloride derivatized Tween 
61 in the noisome formulation was done through monoclonal IgG 
antibodies conjugated to the vesicle surfaces, and are prepared 
using thin film hydration techniques followed by sonication. 
Magnetic niosomes 
Niosomes show its effective magnetic targeting in a combination of 
drug delivery for various applications especially in cancer therapy 
[67]. Encapsulation of both anti-tumoral model drug and magnetic-
EMG 707 ferrofluids into the aqueous core of niosome, lead to the 
development of Doxorubicin-loaded magneto-niosomal formulations 
without any additional toxicity [68]. 
Gene delivery 
Niosomes are utilized as a cutaneous gene delivery system for the 
treatment of skin diseases [69]. In a study by Raghavachari and Fahl 
[70], nonionic liposomes in rat skin cells; affords a competent 
delivery of beta-galactosidase/luciferase DNAs and it is illustrated as 
that generally DNA is a sequence of base-pairs of four different 
nucleotide bases [71]. 
Anticancer drug delivery 
Niosomes comprising a non-ionic surfactant, cholesterol and dicetyl 
phosphate encapsulating methotrexate (MTX) lead to the increased 
absorption from the gastrointestinal tract with subsequent oral 
ingestion. Excessive uptake of MTX into the liver following the 
intravenous administration of the niosomes as compared to MTX, 
administered either orally or intravenously. 
Other anticancer agents such as vincristine [72] bleomycin [73] and 
paclitaxel [74] show reduced toxicity with improved anticancer activity.  
Transdermal delivery 
Stratum corneum, the intracellular lipid barrier is significantly looser 
and more permeable for the particles such as niosomes [75]. Niosomes 
were used as a carrier for the transdermal delivery of ketorolac–a potent 
nonsteroidal anti-inflammatory drug with significant improvement in 
drug permeation with reduced lag time [76]. 
Ammonium glycyrrhizinate, niosomes of the natural compound, 
having effective anti-inflammatory activity formulated with the help 
of a new nonionic surfactant, ậ ὠ-hexadecyl-bis-(1-aza-18-crown-6) 
(bola surfactant)–span 80 and cholesterol in a ratio of 2: 3: 1 to 
increase the intracellular delivery by bola surfactant. Experiments 
showed that the bola niosomes could promote the intracellular 
uptake of ammonium glycerrhizinic acid [77]. 
Improved stability of peptide drugs 
Stability of peptide drug namely, 8-arginin vasopressin, 9-
glycinamide-w 33 was increased significantly by using niosomes. A 
non-ionic surfactant Span 60 has high conflicts in incorporating 
proteolytic enzymes, but in the presence of sodium deoxycholate 
and proper storage temperature, the stability of niosomes is found 
to be excellent [78]. 
In ophthalmic drug delivery 
Gentamicin sulphate, a water-soluble antibiotic shows an extensive 
alteration in the release rate during its experimental studies. 
Moreover, in contrast to the regular drug sample solution, niosomal 
formulation of drug exhibit sluggish release [79]. Timolol maleate 
(0.25%) niosomes, formulated via coating with chitosan shows more 
effect on intraocular tension with fewer side effects as compared to 
the marketed products [80]. 
In the treatment of localized psoriasis  
The limited applications of Methotrexate for the treatment of 
psoriasis were because of its manufacturing difficulties. It was then 
overcome by methotrexate niosomes, using chitosan as the polymer, 
with the promising results [81]. 
In leishmaniasis 
Generally, leishmaniasis parasite primarily affects the cells of the 
liver and spleen. Antimonials, the commonly used drug may damage 
the heart; liver; kidney etc. The incorporation of these drugs like 
sodium stibogluconate into niosomes improves the efficacy of the 
drug [82]. The additive effect was observed when two doses were 
given on successive days. Moreover, the higher level of antimony in 
the liver after its intravenous (i. v.) administration in mice is found 
in niosomes drug formulation [83]. 
In diagnostic imaging  
Niosomes-as a carrier for radiopharmaceuticals. It also shows site 
specificity for spleen and liver using 99mTc labelled DTPA 
containing niosomes for their imaging studies [84]. Improved 
tumour targeting of a paramagnetic agent is obtained by conjugated 
niosomal formulations-gadobenate with (N-palmitoyl-glucosamine, 
NPG), PEG 4400 and both PEG and NPG [85]. 
Carrier for haemoglobin 
Niosomes being a carrier for haemoglobin plays a major role. A 
super-imposable curve on free haemoglobin curve is obtained by the 
niosomal haemoglobin suspension [86, 87]. 
Mothilal et al. 




L’Oréal developed and patented niosomes in the year 1970s and 
1980s who devised the primary report of non-ionic surfactant 
vesicles for cosmetic applications. And the first product ‘Niosome’ 
was introduced in 1987 by Lancôme. Niosomes have intense ability 
to progress the bioavailability of poorly absorbed substances; raise 
the stability of entrapped drugs and finally enhances skin 
penetration, thus paves the way for niosomes in the area of cosmetic 
and skin care applications [88].  
Vaccine delivery 
For peroral vaccine delivery system and for topical 
immunization, niosomes attains good attention. Niosomes for 
topical DNA delivery of Hepatitis B surface antigen (HBsAg) 
were formulated, using the reverse phase evaporation method 
using Span 85 and cholesterol. The immune stimulating activity 
was investigated and was noted that topical niosomes elicited a 
comparable serum antibody titer and endogenous cytokines 
levels as compared to topical liposomes and intramuscular (i. m) 
recombinant HBsAg [89,90]. 
CONCLUSION 
Niosomes are becoming an efficient and effective move towards a 
recent drug delivery. These were used in the modern 
pharmaceutical industry due to their remarkable advantages over 
conventional vesicular delivery systems. Among all the applications 
of niosomal technology, the development of a suitable niosomal 
carrier to encapsulate neuroactive compounds is incredibly 
promising. The nose to brain delivery route has the potential to 
become alternative of invasive methods of drug delivery to the brain 
regarding improved drug absorption and less systemic adverse effect. 
To enjoy the advantages, the limitations of variable absorption or 
nasal toxicity must be exterminated. The goal of development of 
niosomes is to control the release of drug in a sustained manner, a 
further change in the distribution profile of drug and targeting to the 
specific body site. Thus as an effective tool now and then for various 
therapeutic substances and the responsibility lies on future research 
scientists to successfully yoke its potential in various purposes for the 
aid of people. 
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